Request Free Sample ×
US Endoprosthesis Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Endoprosthesis Market

ID: MRFR/MED/12339-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Endoprosthesis Market Research Report: By Product (Knee, Hip, Shoulder, Elbow, Finger/Hand, Ankle/Foot), By Knee (Primary, Partial, Revision Knee Replacement, Tumor, Custom Made), By Hip (Primary, Partial, Revision Hip Replacement, Tumor, Custom Made), By Shoulder (Primary, Revision Shoulder Replacement, Tumor, Custom Made) and By Elbow (Total Elbow, Radial Head Replacement, Tumor, Custom Made) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Endoprosthesis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Product (USD Million)
  49.     4.1.1 Knee
  50.     4.1.2 Hip
  51.     4.1.3 Shoulder
  52.     4.1.4 Elbow
  53.     4.1.5 Finger/Hand
  54.     4.1.6 Ankle/Foot
  55.   4.2 Pharmaceutical, BY Knee (USD Million)
  56.     4.2.1 Primary
  57.     4.2.2 Partial
  58.     4.2.3 Revision Knee Replacement
  59.     4.2.4 Tumor
  60.     4.2.5 Custom Made
  61.   4.3 Pharmaceutical, BY Hip (USD Million)
  62.     4.3.1 Primary
  63.     4.3.2 Partial
  64.     4.3.3 Revision Hip Replacement
  65.     4.3.4 Tumor
  66.     4.3.5 Custom Made
  67.   4.4 Pharmaceutical, BY Shoulder (USD Million)
  68.     4.4.1 Primary
  69.     4.4.2 Revision Shoulder Replacement
  70.     4.4.3 Tumor
  71.     4.4.4 Custom Made
  72.   4.5 Pharmaceutical, BY Elbow (USD Million)
  73.     4.5.1 Total Elbow
  74.     4.5.2 Radial Head Replacement
  75.     4.5.3 Tumor
  76.     4.5.4 Custom Made
  77. 5 SECTION V: COMPETITIVE ANALYSIS
  78.   5.1 Competitive Landscape
  79.     5.1.1 Overview
  80.     5.1.2 Competitive Analysis
  81.     5.1.3 Market share Analysis
  82.     5.1.4 Major Growth Strategy in the Pharmaceutical
  83.     5.1.5 Competitive Benchmarking
  84.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  85.     5.1.7 Key developments and growth strategies
  86.       5.1.7.1 New Product Launch/Service Deployment
  87.       5.1.7.2 Merger & Acquisitions
  88.       5.1.7.3 Joint Ventures
  89.     5.1.8 Major Players Financial Matrix
  90.       5.1.8.1 Sales and Operating Income
  91.       5.1.8.2 Major Players R&D Expenditure. 2023
  92.   5.2 Company Profiles
  93.     5.2.1 Stryker Corporation (US)
  94.       5.2.1.1 Financial Overview
  95.       5.2.1.2 Products Offered
  96.       5.2.1.3 Key Developments
  97.       5.2.1.4 SWOT Analysis
  98.       5.2.1.5 Key Strategies
  99.     5.2.2 Zimmer Biomet Holdings Inc (US)
  100.       5.2.2.1 Financial Overview
  101.       5.2.2.2 Products Offered
  102.       5.2.2.3 Key Developments
  103.       5.2.2.4 SWOT Analysis
  104.       5.2.2.5 Key Strategies
  105.     5.2.3 DePuy Synthes (US)
  106.       5.2.3.1 Financial Overview
  107.       5.2.3.2 Products Offered
  108.       5.2.3.3 Key Developments
  109.       5.2.3.4 SWOT Analysis
  110.       5.2.3.5 Key Strategies
  111.     5.2.4 Medtronic plc (IE)
  112.       5.2.4.1 Financial Overview
  113.       5.2.4.2 Products Offered
  114.       5.2.4.3 Key Developments
  115.       5.2.4.4 SWOT Analysis
  116.       5.2.4.5 Key Strategies
  117.     5.2.5 Smith & Nephew plc (GB)
  118.       5.2.5.1 Financial Overview
  119.       5.2.5.2 Products Offered
  120.       5.2.5.3 Key Developments
  121.       5.2.5.4 SWOT Analysis
  122.       5.2.5.5 Key Strategies
  123.     5.2.6 Boston Scientific Corporation (US)
  124.       5.2.6.1 Financial Overview
  125.       5.2.6.2 Products Offered
  126.       5.2.6.3 Key Developments
  127.       5.2.6.4 SWOT Analysis
  128.       5.2.6.5 Key Strategies
  129.     5.2.7 NuVasive Inc (US)
  130.       5.2.7.1 Financial Overview
  131.       5.2.7.2 Products Offered
  132.       5.2.7.3 Key Developments
  133.       5.2.7.4 SWOT Analysis
  134.       5.2.7.5 Key Strategies
  135.     5.2.8 Aesculap Implant Systems GmbH (DE)
  136.       5.2.8.1 Financial Overview
  137.       5.2.8.2 Products Offered
  138.       5.2.8.3 Key Developments
  139.       5.2.8.4 SWOT Analysis
  140.       5.2.8.5 Key Strategies
  141.   5.3 Appendix
  142.     5.3.1 References
  143.     5.3.2 Related Reports
  144. 6 LIST OF FIGURES
  145.   6.1 MARKET SYNOPSIS
  146.   6.2 US MARKET ANALYSIS BY PRODUCT
  147.   6.3 US MARKET ANALYSIS BY KNEE
  148.   6.4 US MARKET ANALYSIS BY HIP
  149.   6.5 US MARKET ANALYSIS BY SHOULDER
  150.   6.6 US MARKET ANALYSIS BY ELBOW
  151.   6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
  152.   6.8 RESEARCH PROCESS OF MRFR
  153.   6.9 DRO ANALYSIS OF PHARMACEUTICAL
  154.   6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  155.   6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  156.   6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  157.   6.13 PHARMACEUTICAL, BY PRODUCT, 2024 (% SHARE)
  158.   6.14 PHARMACEUTICAL, BY PRODUCT, 2024 TO 2035 (USD Million)
  159.   6.15 PHARMACEUTICAL, BY KNEE, 2024 (% SHARE)
  160.   6.16 PHARMACEUTICAL, BY KNEE, 2024 TO 2035 (USD Million)
  161.   6.17 PHARMACEUTICAL, BY HIP, 2024 (% SHARE)
  162.   6.18 PHARMACEUTICAL, BY HIP, 2024 TO 2035 (USD Million)
  163.   6.19 PHARMACEUTICAL, BY SHOULDER, 2024 (% SHARE)
  164.   6.20 PHARMACEUTICAL, BY SHOULDER, 2024 TO 2035 (USD Million)
  165.   6.21 PHARMACEUTICAL, BY ELBOW, 2024 (% SHARE)
  166.   6.22 PHARMACEUTICAL, BY ELBOW, 2024 TO 2035 (USD Million)
  167.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  168. 7 LIST OF TABLES
  169.   7.1 LIST OF ASSUMPTIONS
  170.     7.1.1
  171.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  172.     7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  173.     7.2.2 BY KNEE, 2025-2035 (USD Million)
  174.     7.2.3 BY HIP, 2025-2035 (USD Million)
  175.     7.2.4 BY SHOULDER, 2025-2035 (USD Million)
  176.     7.2.5 BY ELBOW, 2025-2035 (USD Million)
  177.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  178.     7.3.1
  179.   7.4 ACQUISITION/PARTNERSHIP
  180.     7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Product (USD Million, 2025-2035)

  • Knee
  • Hip
  • Shoulder
  • Elbow
  • Finger/Hand
  • Ankle/Foot

Pharmaceutical By Knee (USD Million, 2025-2035)

  • Primary
  • Partial
  • Revision Knee Replacement
  • Tumor
  • Custom Made

Pharmaceutical By Hip (USD Million, 2025-2035)

  • Primary
  • Partial
  • Revision Hip Replacement
  • Tumor
  • Custom Made

Pharmaceutical By Shoulder (USD Million, 2025-2035)

  • Primary
  • Revision Shoulder Replacement
  • Tumor
  • Custom Made

Pharmaceutical By Elbow (USD Million, 2025-2035)

  • Total Elbow
  • Radial Head Replacement
  • Tumor
  • Custom Made

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓